XML 52 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details) - USD ($)
$ in Thousands
12 Months Ended
Jul. 20, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Assets        
Cash and cash equivalents   $ 193,513 $ 291,049  
Prepaid expenses and other current assets   21,630 29,559  
Equity and long-term investments   444,432 363,859  
Total assets   1,243,507 1,231,497  
Liabilities and Stockholders Equity        
Current liabilities   38,134 134,968  
Total liabilities and stockholders' equity   1,243,507 1,231,497  
Income statements        
Total net revenue   310,463 331,339 $ 391,866
Other income, net   (4,969) (3,373) (3,626)
Income tax expense, net   14,376 66,687 76,439
Net income   179,722 220,262 368,837
Royalty revenue        
Income statements        
Total net revenue   238,846 $ 311,645 391,866
Theravance Respiratory Company, LLC        
CONSOLIDATED ENTITIES        
Ownership interest in LLC     15.00%  
Proceeds from sale of economic interest under Equity Purchase Agreement $ 277,500      
Contingent sales based milestone payment 50,000      
Cash distribution 4,400      
Total carrying value of investments $ 39,400      
Income statements        
Operating expenses     $ (332) [1] (3,956)
Income from operations     71,697 [1] 122,732
Other income, net     10 [1] 0
Realized loss     (39,386) [1] 0
Income tax expense, net     1 [1] 0
Changes in fair values of equity and long-term investments     (8,884) [1] (1,541)
Net income     23,438 [1] 121,191
Theravance Respiratory Company, LLC | Royalty revenue        
Income statements        
Total net revenue     72,029 [1] 126,688
ISP Fund LP        
Assets        
Total assets   311,800 320,600  
Income statements        
Changes in fair values of equity and long-term investments   $ 2,400 $ 6,800 $ 10,500
[1]

(1) The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.